Self-Assembled PEGylated Nanocubes Based on Hydrophobic Camptothecin and Doxorubicin for Combinational Therapy of Colorectal Cancer DOI

Yi‐Fei Xue,

Xiaojie Song,

Xiao-Qing Ling

et al.

ACS Applied Materials & Interfaces, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 25, 2024

Nanoassemblies based on drug conjugates with high loading efficiency and stability have been regarded as promising candidates for the next generation of formulations. However, they are mostly amphiphilic. Here, a dual-hydrophobic conjugate-based nanoassembly has created enhanced synergistic antiproliferation against colorectal cancer cells. Camptothecin (CPT) doxorubicin (DOX) were chosen hydrophobic drugs covalently linked disulfide bond (-ss-). The synthesized CPT-ss-DOX can self-assemble into nanocubes (NCs) in an aqueous solution assistance small amount polyethylene glycol (PEG), named PEGylated NCs. NCs approximately 111.8 nm, possessing crystal structure very low critical aggregation concentration (8.36 μg·mL

Language: Английский

Nanomedicine in Immunotherapy for Non‐Small Cell Lung Cancer: Applications and Perspectives DOI Open Access
Shuangsi Liao, Xiaoling Li, You Lü

et al.

Small Methods, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 28, 2025

Abstract Non‐small cell lung cancer (NSCLC) has a strikingly high incidence rate globally. Although immunotherapy brings great breakthrough in its clinical treatment of NSCLC, significant challenges still need to be overcome. The development novel multi‐functional nanomedicines the realm tumor offers promising opportunities for NSCLC patients, as exhibit advantages, including specific targeting cells, improved drug bioavailability, reduced systemic toxicity, and overcoming immune resistance. In this review, core features current status strategies checkpoint blockade, antibody–drug conjugates, engagers, adoptive vaccines, are surveyed. Particular emphasis is placed on recent that boost these strategies. Nanomedicine can provide perspectives immunotherapy.

Language: Английский

Citations

1
“On/off”-switchable crosslinked PTX-nanoformulation with improved precise delivery for NSCLC brain metastases and restrained adverse reaction over nab-PTX DOI
Shuaijun Li,

Caiting Meng,

Qian Hao

et al.

Biomaterials, Journal Year: 2024, Volume and Issue: 307, P. 122537 - 122537

Published: March 14, 2024

Language: Английский

Citations

8
Nanomedicine for targeting brain Neurodegeneration: Critical barriers and circadian rhythm Considerations DOI Creative Commons
Laura Pineiro‐Alonso,

Inés Rubio-Prego,

Alexandra Lobyntseva

et al.

Advanced Drug Delivery Reviews, Journal Year: 2025, Volume and Issue: unknown, P. 115606 - 115606

Published: May 1, 2025

The development of novel therapies for central nervous system (CNS) diseases, particularly neurodegenerative disorders like Alzheimer's disease (AD), is a critical global health priority. Biotherapeutics, such as monoclonal antibodies (mAbs) and RNA-based therapies, have shown potential treating brain disorders. However, their clinical progress limited by difficult access to targets. At the preclinical level, nanotechnology has been shown, help these molecules overcome biological barriers that imped adequate delivery. This review highlights advances in this area challenges translation clinic. Key nanotechnology-based strategies, surface modifications utilizing endogenous protein corona, functionalization with targeting ligands, therapeutic ultrasound-mediated microbubble oscillation were analyzed. Additionally, line focus Special Issue, integrates concept chronotherapy, on AD treatment, highlighting idea that, aligning nanoparticle (NP)-based drug delivery circadian rhythms, it may be possible improve outcomes. Finally, article analyzes current strategies CNS trials provides future directions within frame, notably AD.

Language: Английский

Citations

0
STAT3-specific nanocarrier for shRNA/drug dual delivery and tumor synergistic therapy DOI Creative Commons
Le Sun,

Jishang Sun,

Cuiyao Li

et al.

Bioactive Materials, Journal Year: 2024, Volume and Issue: 41, P. 137 - 157

Published: July 17, 2024

Language: Английский

Citations

2
Research progress and challenges of the PD-1/PD-L1 axis in gliomas DOI Creative Commons

Dong Jiacheng,

Jiayue Cui,

Guo Ying

et al.

Cell & Bioscience, Journal Year: 2024, Volume and Issue: 14(1)

Published: Sept. 27, 2024

Language: Английский

Citations

2
Combinatory Immunotherapy for Glioblastoma Treatment DOI
Muhammad Ijaz, Ikram Hasan,

Jiang Zhi-ru

et al.

Advanced Therapeutics, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 2, 2024

Abstract Despite advancements in the treatment of glioblastoma, it faces challenges due to tumor heterogeneity, blood‐brain barrier, recurrence, immune evasion, and conventional strategies, leading low survival a poor prognosis. Therefore, is crucial develop novel, useful strategies for improving brain distribution overcome barriers (BBB) help glioblastoma. Conventional immunotherapy like checkpoint inhibitors, CAR‐T cell therapy, monoclonal antibodies, cancer vaccines, adoptive transfer often suffers from therapeutic outcomes because singular therapy generally has shortcomings, such as cold microenvironment tumors. In contrast, emerging combinatory integrated with chemo‐immunotherapy, photothermal‐immunotherapy, radio‐immunotherapy shown great promise modulate tumoral boost outcomes. This review discusses GBM, its impact on immunological effects, current methods, advanced studies. It also introduces combinational GBM traditional therapies surgery‐immunotherapy, radiotherapy‐immunotherapy. future, anticipated that this article will provide beneficial information path strategy innovative, efficient combination

Language: Английский

Citations

2
Revitalizing Bacillus Calmette–Guérin Immunotherapy for Bladder Cancer: Nanotechnology and Bioengineering Approaches DOI Creative Commons
M. Lv, S. Y. Shang,

Kepu Liu

et al.

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(8), P. 1067 - 1067

Published: Aug. 15, 2024

Bacillus Calmette-Guérin (BCG) immunotherapy has been a cornerstone treatment for non-muscle-invasive bladder cancer decades and still faces challenges, such as severe immune adverse reactions, which reduce its use first-line treatment. This review examines BCG therapy's history, mechanisms, current status, highlighting how nanotechnology bioengineering are revitalizing application. We discuss novel nanocarrier systems aimed at enhancing BCG's efficacy while mitigating specific side effects. These approaches promise improved tumor targeting, better drug loading, an enhanced stimulation of anti-tumor responses. Key strategies involve using materials liposomes, polymers, magnetic particles to encapsulate or functional cell wall components. Additionally, co-delivering with chemotherapeutics enhances targeting tumor-killing effects reducing toxicity, some studies even achieving synergistic While most remain experimental, this research direction offers hope overcoming limitations advancing immunotherapy. Further elucidation mechanisms rigorous safety evaluations new delivery will be crucial translating these innovations into clinical practice.

Language: Английский

Citations

1
Self-Assembled PEGylated Nanocubes Based on Hydrophobic Camptothecin and Doxorubicin for Combinational Therapy of Colorectal Cancer DOI

Yi‐Fei Xue,

Xiaojie Song,

Xiao-Qing Ling

et al.

ACS Applied Materials & Interfaces, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 25, 2024

Nanoassemblies based on drug conjugates with high loading efficiency and stability have been regarded as promising candidates for the next generation of formulations. However, they are mostly amphiphilic. Here, a dual-hydrophobic conjugate-based nanoassembly has created enhanced synergistic antiproliferation against colorectal cancer cells. Camptothecin (CPT) doxorubicin (DOX) were chosen hydrophobic drugs covalently linked disulfide bond (-ss-). The synthesized CPT-ss-DOX can self-assemble into nanocubes (NCs) in an aqueous solution assistance small amount polyethylene glycol (PEG), named PEGylated NCs. NCs approximately 111.8 nm, possessing crystal structure very low critical aggregation concentration (8.36 μg·mL

Language: Английский

Citations

1